Montelukast
CLINICAL USE
Prophylaxis of asthma
DOSE IN NORMAL RENAL FUNCTION
10 mg at night
PHARMACOKINETICS
Molecular weight                           :608.2 (as sodium salt) %Protein binding                           :>99 %Excreted unchanged in urine     : <0.2 Volume of distribution (L/kg)       :8–11 litreshalf-life – normal/ESRD (hrs)      :2.7–5.5 DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. Dose as in normal renal function HD                     :Not dialysed. Dose as in normal renal functionHDF/high flux   :Not dialysed. Dose as in normal renal functionCAV/VVHD      :Not dialysed. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsNone known ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
Metabolites have minimal therapeutic activity.
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home